PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
The Pharma Data
MAY 4, 2021
There was a single voting question focused on whether the proposed risk evaluation and mitigation strategy (REMS) for tanezumab will ensure its benefits outweigh its risks, and the Committee voted 1 in favor and 19 against. View source version on businesswire.com : [link]. Amy Rose 212.733.7410. Chuck Triano 212.733.3901. Bryan Dunn 212.733.8917.
40 
Let's personalize your content